Prospective study of fertility‐sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women. Issue 2 (4th October 2021)

• Record Type: Journal Article
• Authors: Ouasti, Samia; Bucau, Margot; Larouzee, Elise; Clement De Givry, Sebastien; Chabbert‐Buffet, Nathalie; Koskas, Martin
• Is Part Of: International journal of gynaecology and obstetrics. Volume 157:Issue 2(2022)
• Page Start: 452
• Page End: 457
• Publication Date: 2021-10-04
• Subjects: atypical hyperplasia -- chlormadinone acetate -- endometrial carcinoma -- fertility‐sparing treatment; Gynecology -- Periodicals; Obstetrics -- Periodicals; Electronic journals; 618
• DOI: 10.1002/ijgo.13941
• Languages: English
• ISSNs: 0020-7292

Abstract

Abstract: Objective: To confirm that the efficiency of the use of chlormadinone acetate for 6 months to obtain remission of atypical hyperplasia or endometrial carcinoma is comparable to that of the use of other fertility‐sparing treatments. Method: The present study is based on the PREFERE prospective registry. All the patients received 3 or 6 months of chlormadinone acetate and were evaluated by hysteroscopic resection and pipelle sampling every 3 months. Results: Ninety‐four patients were included. Seventy‐nine patients achieved complete remission at 6 months (84%). No patients stopped treatment because of a lack of tolerance. Twenty‐four per cent of the patients achieved a live birth. Conclusion: Chlormadinone acetate is an effective and well‐tolerated fertility‐sparing treatment. Its benefits over other progestins are its tolerability, and its absence of contraindications, which make it a good choice for patients with thromboembolism and high vascular risk. Abstract : Chlormadinone acetate is an effective fertility‐sparing treatment because of its tolerance and the absence of contraindications for patients with history of thromboembolism and vascular risk.